Clinical trial · Interventional
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
Prospective Study of Circulating Tumor DNA Kinetics Post R-CHOP Type Treatment of Diffuse Large B Cell Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma (DLBCL). Modelizing the short-term kinetics of ctDNA would help to determine the optimal time-point for ctDNA follow-up. The investigators hypothesize that the greater ctDNA release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Measure of the circulating tumor DNA | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Kinetics of circulating tumor DNA
- interventionNames
- Other: Measure of the circulating tumor DNA
Primary outcomes (1)
- measure
- Analysis of circulating tumor DNA kinetics
- timeFrame
- 21 days
- description
- Blood assessment to measure circulating tumor concentration
Secondary outcomes (1)
- measure
- Correlation between circulating tumor DNA concentration and metabolic volume
- timeFrame
- 6 months
- description
- comparison between circulating tumoral concentration and metabolic volume measured on TEP
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * Diffuse Large B Cell Lymphoma * TEP-TDM at diagnosis * Inform Consent form signed * Performance status 0 or 1 * Hospitalized on clinician decision for first cycle of R-CHOP or R-miniCHOP Exclusion Criteria: * Histology other than Diffuse Large B Cell * Patient under guardianship or curatorship * Incapacity to understand the study or conform to the constraints of the study (language barrier, psychological barrier, geographic barrier…)
References
Publications (0)
Data not yet available